Alto Neuroscience Class Action Lawsuit Filed Against Officers.
PorAinvest
martes, 2 de septiembre de 2025, 10:04 am ET1 min de lectura
ANRO--
The complaint alleges that Alto Neuroscience, Inc. made false statements and concealed material information regarding its product pipeline, ALTO-100. Specifically, the company is accused of overstating the effectiveness of ALTO-100 in treating major depressive disorder, which led to an overestimation of the clinical, regulatory, and commercial prospects of the product. As a result, the lawsuit claims that Alto's business and financial prospects were also overstated, and the company's public statements were materially false and misleading.
The class action lawsuit seeks to recover losses on behalf of investors who purchased Alto common stock or other securities during the relevant time frame. Investors who believe they were adversely affected by the alleged securities fraud are encouraged to contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
The deadline to request that the Court appoint you as lead plaintiff is September 19, 2025. Participation in the lawsuit is free of cost, and investors may be entitled to compensation without any out-of-pocket expenses.
Levi & Korsinsky, LLP has a proven track record in securities litigation, having secured hundreds of millions of dollars for aggrieved shareholders and ranking among the top firms in the United States for seven consecutive years [1][2].
References:
[1] https://www.morningstar.com/news/pr-newswire/20250902ny61586/levi-korsinsky-notifies-shareholders-of-alto-neuroscience-incanro-of-a-class-action-lawsuit-and-an-upcoming-deadline
[2] https://www.marketscreener.com/news/levi-korsinsky-notifies-shareholders-of-alto-neuroscience-inc-anro-of-a-class-action-lawsuit-an-ce7c50d3de8df721
A class action lawsuit has been filed against Alto Neuroscience, Inc. (NYSE: ANRO) and certain officers for alleged securities violations. The lawsuit claims that the company and its officers misled investors in its initial public offering and during the Class Period (February 2, 2024 to October 22, 2024). The plaintiff seeks to recover damages on behalf of investors who purchased Alto securities during this time.
Alto Neuroscience, Inc. (NYSE: ANRO) is facing a class action lawsuit alleging securities fraud. The lawsuit, filed by Levi & Korsinsky, LLP, claims that the company and its officers misled investors during the initial public offering and the subsequent class period from February 2, 2024, to October 22, 2024.The complaint alleges that Alto Neuroscience, Inc. made false statements and concealed material information regarding its product pipeline, ALTO-100. Specifically, the company is accused of overstating the effectiveness of ALTO-100 in treating major depressive disorder, which led to an overestimation of the clinical, regulatory, and commercial prospects of the product. As a result, the lawsuit claims that Alto's business and financial prospects were also overstated, and the company's public statements were materially false and misleading.
The class action lawsuit seeks to recover losses on behalf of investors who purchased Alto common stock or other securities during the relevant time frame. Investors who believe they were adversely affected by the alleged securities fraud are encouraged to contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
The deadline to request that the Court appoint you as lead plaintiff is September 19, 2025. Participation in the lawsuit is free of cost, and investors may be entitled to compensation without any out-of-pocket expenses.
Levi & Korsinsky, LLP has a proven track record in securities litigation, having secured hundreds of millions of dollars for aggrieved shareholders and ranking among the top firms in the United States for seven consecutive years [1][2].
References:
[1] https://www.morningstar.com/news/pr-newswire/20250902ny61586/levi-korsinsky-notifies-shareholders-of-alto-neuroscience-incanro-of-a-class-action-lawsuit-and-an-upcoming-deadline
[2] https://www.marketscreener.com/news/levi-korsinsky-notifies-shareholders-of-alto-neuroscience-inc-anro-of-a-class-action-lawsuit-an-ce7c50d3de8df721
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios